{"id":"NCT03188692","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants","officialTitle":"Phase 3 Study of BK1310 Intramuscular Injection in Healthy Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-23","primaryCompletion":"2017-11-02","completion":"2018-08-09","firstPosted":"2017-06-15","resultsPosted":"2025-01-03","lastUpdate":"2025-01-03"},"enrollment":33,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Immunization"],"interventions":[{"type":"BIOLOGICAL","name":"DPT-IPV-Hib (Combined Vaccine)","otherNames":["BK1310"]}],"arms":[{"label":"BK1310","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of an intramuscular injection of BK1310 in healthy infants.","primaryOutcome":{"measure":"Antibody Prevalence Rate Against Anti-PRP With 1 Î¼g/mL or Higher, Diphtheria Toxin, Pertussis, Tetanus Toxin, and Polio Virus, Defined as the Percentage of Participants With the Antibody Against Anti-PRP","timeFrame":"4 weeks after the primary immunization (Visit 4)","effectByArm":[{"arm":"BK1310","deltaMin":97,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":12},"locations":{"siteCount":3,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":33},"commonTop":["Pyrexia","Injection site erythema","Crying","Upper respiratory tract inflammation","Hypersomnia"]}}